NCT05137548 - A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions

Drug Interaction

Interventions

DRUG

ATI-2173 50 mg

ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

DRUG

Tenofovir 300Mg Oral Tablet

Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth

Trial Locations (1)

H3P 3P1

Altasciences, Montreal